Abstract
Purpose: To determine the risk factors for development of neovascular glaucoma (NVG) in patients after an acute central retinal vein occlusion (CRVO). Design: Retrospective cohort study. Methods: Review of medical records of 646 patients with a diagnosis of CRVO between 2013 and 2017 at the Bascom Palmer Eye Institute. Inclusion criteria: (1) CRVO onset to presentation <90 days; (2) absence of anterior segment neovascularization on presentation; (3) no intravitreal anti–vascular endothelial growth factor (anti-VEGF) injection before presentation. Patients meeting inclusion criteria were screened for potential risk factors for development of NVG. Risk of developing NVG was assessed with Kaplan-Meier survival analysis and Cox proportional hazards models. Results: Thirteen of 98 patients (13%) who met inclusion criteria developed NVG. The mean adjusted time to NVG diagnosis from onset of CRVO-related symptoms was 212 days. Patients presenting with a worse initial visual acuity (P = .034), a relative afferent pupillary defect (RAPD) (P = .002), or a history of systemic hypertension (P = .026) had an increased risk of NVG compared to those who did not. Age, body mass index, history of glaucoma, history of diabetes, and central retinal thickness were not significantly associated with development of NVG. Conclusions: Risk factors for NVG development included history of systemic hypertension, worse visual acuity on presentation, and RAPD on presentation. Patients presenting with these findings should be followed at closer intervals and informed of the greater risk for neovascularization. Intravitreal anti-VEGF therapy delayed but did not prevent NVG.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 62-69 |
| Number of pages | 8 |
| Journal | American journal of ophthalmology |
| Volume | 204 |
| DOIs | |
| State | Published - Aug 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. / Rong, Andrew J.; Swaminathan, Swarup S.; Vanner, Elizabeth A.; Parrish, Richard K.
In: American journal of ophthalmology, Vol. 204, 01.08.2019, p. 62-69.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion
AU - Rong, Andrew J.
AU - Swaminathan, Swarup S.
AU - Vanner, Elizabeth A.
AU - Parrish, Richard K
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Purpose: To determine the risk factors for development of neovascular glaucoma (NVG) in patients after an acute central retinal vein occlusion (CRVO). Design: Retrospective cohort study. Methods: Review of medical records of 646 patients with a diagnosis of CRVO between 2013 and 2017 at the Bascom Palmer Eye Institute. Inclusion criteria: (1) CRVO onset to presentation <90 days; (2) absence of anterior segment neovascularization on presentation; (3) no intravitreal anti–vascular endothelial growth factor (anti-VEGF) injection before presentation. Patients meeting inclusion criteria were screened for potential risk factors for development of NVG. Risk of developing NVG was assessed with Kaplan-Meier survival analysis and Cox proportional hazards models. Results: Thirteen of 98 patients (13%) who met inclusion criteria developed NVG. The mean adjusted time to NVG diagnosis from onset of CRVO-related symptoms was 212 days. Patients presenting with a worse initial visual acuity (P = .034), a relative afferent pupillary defect (RAPD) (P = .002), or a history of systemic hypertension (P = .026) had an increased risk of NVG compared to those who did not. Age, body mass index, history of glaucoma, history of diabetes, and central retinal thickness were not significantly associated with development of NVG. Conclusions: Risk factors for NVG development included history of systemic hypertension, worse visual acuity on presentation, and RAPD on presentation. Patients presenting with these findings should be followed at closer intervals and informed of the greater risk for neovascularization. Intravitreal anti-VEGF therapy delayed but did not prevent NVG.
AB - Purpose: To determine the risk factors for development of neovascular glaucoma (NVG) in patients after an acute central retinal vein occlusion (CRVO). Design: Retrospective cohort study. Methods: Review of medical records of 646 patients with a diagnosis of CRVO between 2013 and 2017 at the Bascom Palmer Eye Institute. Inclusion criteria: (1) CRVO onset to presentation <90 days; (2) absence of anterior segment neovascularization on presentation; (3) no intravitreal anti–vascular endothelial growth factor (anti-VEGF) injection before presentation. Patients meeting inclusion criteria were screened for potential risk factors for development of NVG. Risk of developing NVG was assessed with Kaplan-Meier survival analysis and Cox proportional hazards models. Results: Thirteen of 98 patients (13%) who met inclusion criteria developed NVG. The mean adjusted time to NVG diagnosis from onset of CRVO-related symptoms was 212 days. Patients presenting with a worse initial visual acuity (P = .034), a relative afferent pupillary defect (RAPD) (P = .002), or a history of systemic hypertension (P = .026) had an increased risk of NVG compared to those who did not. Age, body mass index, history of glaucoma, history of diabetes, and central retinal thickness were not significantly associated with development of NVG. Conclusions: Risk factors for NVG development included history of systemic hypertension, worse visual acuity on presentation, and RAPD on presentation. Patients presenting with these findings should be followed at closer intervals and informed of the greater risk for neovascularization. Intravitreal anti-VEGF therapy delayed but did not prevent NVG.
UR - http://www.scopus.com/inward/record.url?scp=85067579787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067579787&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.02.038
DO - 10.1016/j.ajo.2019.02.038
M3 - Article
C2 - 31277883
AN - SCOPUS:85067579787
VL - 204
SP - 62
EP - 69
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -